NCT03076515 is a NA clinical trial of Nerivio Migra neurostimulation in Acute Migraine, sponsored by Theranica.

Who is sponsoring NCT03076515?

NCT03076515 is sponsored by Theranica.

What drugs are being tested in NCT03076515?

Interventions in NCT03076515: Nerivio Migra neurostimulation, Sham Nerivio Migra.

What condition does NCT03076515 study?

NCT03076515 studies Acute Migraine.

Is NCT03076515 still recruiting?

NCT03076515 is currently terminated. Last updated 17 July 2025.

Are results published for NCT03076515?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-17 · How we verify

NCT03076515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Migraine Treatment With Nerivio Migra Neurostimulation Device

Terminated NA Results posted Last updated 17 July 2025

What this trial tests

NA trial testing Nerivio Migra neurostimulation in Acute Migraine in 120 participants. Terminated before completion.

Timeline

2 April 2017

Primary endpoint
31 January 2018

1 April 2018

Quick facts

Lead sponsor	Theranica
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	2 April 2017
Primary completion	31 January 2018
Estimated completion	1 April 2018
Sites	8 locations across United States, Israel

Drugs / interventions tested

Nerivio Migra neurostimulation
Sham Nerivio Migra

Conditions studied

Acute Migraine — all drugs for Acute Migraine →

Sponsor

Theranica — full company profile →

Who can join

Adults 18 to 75, any sex, with Acute Migraine. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants With Pain Relief 2 Hours Post Treatment Primary · 2 hours post treatment

Percentage of participants reporting pain relief from pain (pain reduction from 3 or 2 to 1 or 0 or pain reduction from 1 to 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks

Group	Value	95% CI
Nerivio Migra Active	36.3
Nerivio Migra Placebo	27.2

Sponsor's own description

This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Theranica trials

Trials by the same sponsor.

NCT05523310 — Observational Study to Assess Migraine Prediction Tool · suspended
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07336420 — Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment · Phase 4 · completed
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT06976723 — Nerivio Efficacy by Time of Treatment Onset · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03076515 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Theranica
Last refreshed: 17 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03076515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing